SLC5A2 and type 2 diabetes mellitus: (Naaman & Bakris, 2023; Neuen et al., 2024, 2025) Along with angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers, SGLT2 inhibitors, GLP‐1 agonists, and finerenone have been shown to improve renal and cardiovascular outcomes in patients with type 2 diabetes and albuminuric CKD.